Biotech News
Indivior to Participate in Upcoming Investor Conferences
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences:
2026 Jefferies Global Healthcare Conference – New York, NY – June 3 rd Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 3rd and will also participate in a fireside chat on Wednesday, June 3rd at 11:05 a.m. U.S. EDT. Interested investors should contact their Jefferies representative to schedule a meeting. The fireside chat will be publicly available and can be accessed using the following weblink: Jefferies Webcast Link .
Goldman Sachs 47 th Annual Global Healthcare Conference 2026 – Miami, FL – June 8 th Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Monday, June 8th. Interested investors should contact their Goldman Sachs representative to schedule a meeting.
About Indivior As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit https://www.indivior.com/ to learn more. Connect with Indivior on LinkedIn by visiting https://www.linkedin.com/company/indivior .
For Further Information
Investors: Jason Thompson Indivior Pharmaceuticals, Inc. Tel: 804-402-7123 E-mail: jason.thompson@indivior.com
